Kurt Kara: We bought this pharmaceutical company for the portfolio

In its December 2023 update, Kurt Kara and the team behind their Value Stocks fund provide an update and developments in the portfolio portfolio. Here they mention, among other things, that the ECB and the Bank of England both rejected the end of the fight against inflation. According to Kara, this put a damper on the market, which was otherwise positively affected by announcements from the Fed to lower interest rates in 2024.

Here they also unveil a new position that they have added to the portfolio: the American pharmaceutical manufacturer Johnson & Johnson. In relation to the portfolio, they write:

The American company Johnson & Johnson, which among other things manufactures products in the healthcare field, was added to the portfolio. The company has consistently demonstrated the ability to deliver high returns on invested capital. The stock was bought at 15 times estimated earnings. We divested the position in Intel to finance the acquisition of Johnson & Johnson. Intel has delivered a good performance in 2023, but in our opinion, Johnson & Johnson was a more attractive company on quality and valuation at the time of acquisition.

Share the news

Disclaimer of liability

The above has been prepared by Børsgade ApS for information purposes and cannot be regarded as a solicitation or recommendation to buy or sell any security. Nor can the information etc. be regarded as recommendations or advice of a legal, accounting or tax nature. Børsgade cannot be held liable for losses caused by customers’/users’ actions – or lack thereof – based on the information in the above. We have made every effort to ensure that the information in the above is complete and accurate, but cannot guarantee this and accept no liability for errors or omissions.

Readers are advised that investing may involve a risk of loss that cannot be determined in advance, and that past performance and price development cannot be used as a reliable indicator of future performance and price development. For further information please contact info@borsgade.dk

You might also find this interesting:

Bill Ackman: 2025 Annual Investor Presentation

In his 2025 Annual Investor Presentation, Bill Ackman provides his view on Pershing Square Holdings (PSH) strategic roadmap. Bill also shares his in depth thoughts on the portfolio and key business developments in the companies he owns such as Nike, Brookfield and Uber.

Terry Smith: The Core Attributes of A Great Investment

In this interview, British investing icon Terry Smith, the manager of the UK’s largest stock fund Fundsmith, shares his lessons after a lifetime of investing. Terry delves into the skills, personality traits, and principles that propelled him from humble beginnings to the top of the investing world.

Aswath Damodaran: DeepSeek crashes the AI Party

In his recent article, NYU professor Aswath Damodaran discusses the disruptive entry of DeepSeek, a Chinese AI company, into the artificial intelligence (AI) landscape and its implications for the broader AI narrative.

Cliff Asness: Get Your Expectations in Line With Reality

In this article, AQR assess the assumption built into today’s market and what that likely will mean for forward returns. These insights aim to guide investors in setting realistic medium-term (5-10 years) expectations while emphasizing the importance of valuation discipline and diversification in navigating compressed risk premia across asset classes.